Pleomorphic xanthoastrocytomas: Institutional experience of 18 patients

Taemin Oh, Gurvinder Kaur, Michelle Madden, Orin Bloch, Andrew T. Parsa

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Pleomorphic xanthoastrocytoma (PXA) is a rare, low-grade glioma (World Health Organization Grade II) that most often presents in the first two decades of life. We summarize and present our institutional experience in the management of these tumors. All patients managed for PXA at the University of California San Francisco were retrospectively identified through chart review. Patient demographics, tumor characteristics, management, and follow-up were extracted using medical records. Primary endpoints were overall (OS) and progression-free survival (PFS). In total, nineteen patients were treated for PXA from 1993-2011. Clinical data were available for analysis in 18 patients. Median OS was 209.0 months after date of surgery, with both 5 year and 10 year survival rates of 94%. In this patient cohort, tumor grade (p = 0.07), age (p = 0.32), and extent of resection (p = 0.58) did not predict OS. The majority of tumors (78%) recurred. Median PFS was 21.7 months, with 5 year and 10 year recurrence-free rates of 28% and 22%. On univariate analysis, tumor grade (p = 0.01), but not age (p = 0.51), size (p = 0.30), or extent of resection (p = 0.21), was the only covariate predictive of PFS. In patients presenting with higher tumor grade, however, earlier recurrence was demonstrated. Furthermore, the majority of recurrences (36%) occurred within the first 6 months post-operatively, which indicates the need to closely follow patients for that time.

Original languageEnglish (US)
Pages (from-to)1767-1772
Number of pages6
JournalJournal of Clinical Neuroscience
Volume21
Issue number10
DOIs
StatePublished - Oct 1 2014
Externally publishedYes

Fingerprint

Disease-Free Survival
Neoplasms
Recurrence
San Francisco
Glioma
Medical Records
Survival Rate
Demography

Keywords

  • Cancer
  • Glioma
  • Management
  • Pleomorphic xanthoastrocytoma
  • Resection
  • Treatment
  • Tumor grade

ASJC Scopus subject areas

  • Surgery
  • Neurology
  • Clinical Neurology
  • Physiology (medical)

Cite this

Pleomorphic xanthoastrocytomas : Institutional experience of 18 patients. / Oh, Taemin; Kaur, Gurvinder; Madden, Michelle; Bloch, Orin; Parsa, Andrew T.

In: Journal of Clinical Neuroscience, Vol. 21, No. 10, 01.10.2014, p. 1767-1772.

Research output: Contribution to journalArticle

Oh, Taemin ; Kaur, Gurvinder ; Madden, Michelle ; Bloch, Orin ; Parsa, Andrew T. / Pleomorphic xanthoastrocytomas : Institutional experience of 18 patients. In: Journal of Clinical Neuroscience. 2014 ; Vol. 21, No. 10. pp. 1767-1772.
@article{1ae416df58034c34ad7707529c28c42e,
title = "Pleomorphic xanthoastrocytomas: Institutional experience of 18 patients",
abstract = "Pleomorphic xanthoastrocytoma (PXA) is a rare, low-grade glioma (World Health Organization Grade II) that most often presents in the first two decades of life. We summarize and present our institutional experience in the management of these tumors. All patients managed for PXA at the University of California San Francisco were retrospectively identified through chart review. Patient demographics, tumor characteristics, management, and follow-up were extracted using medical records. Primary endpoints were overall (OS) and progression-free survival (PFS). In total, nineteen patients were treated for PXA from 1993-2011. Clinical data were available for analysis in 18 patients. Median OS was 209.0 months after date of surgery, with both 5 year and 10 year survival rates of 94{\%}. In this patient cohort, tumor grade (p = 0.07), age (p = 0.32), and extent of resection (p = 0.58) did not predict OS. The majority of tumors (78{\%}) recurred. Median PFS was 21.7 months, with 5 year and 10 year recurrence-free rates of 28{\%} and 22{\%}. On univariate analysis, tumor grade (p = 0.01), but not age (p = 0.51), size (p = 0.30), or extent of resection (p = 0.21), was the only covariate predictive of PFS. In patients presenting with higher tumor grade, however, earlier recurrence was demonstrated. Furthermore, the majority of recurrences (36{\%}) occurred within the first 6 months post-operatively, which indicates the need to closely follow patients for that time.",
keywords = "Cancer, Glioma, Management, Pleomorphic xanthoastrocytoma, Resection, Treatment, Tumor grade",
author = "Taemin Oh and Gurvinder Kaur and Michelle Madden and Orin Bloch and Parsa, {Andrew T.}",
year = "2014",
month = "10",
day = "1",
doi = "10.1016/j.jocn.2014.04.002",
language = "English (US)",
volume = "21",
pages = "1767--1772",
journal = "Journal of Clinical Neuroscience",
issn = "0967-5868",
publisher = "Churchill Livingstone",
number = "10",

}

TY - JOUR

T1 - Pleomorphic xanthoastrocytomas

T2 - Institutional experience of 18 patients

AU - Oh, Taemin

AU - Kaur, Gurvinder

AU - Madden, Michelle

AU - Bloch, Orin

AU - Parsa, Andrew T.

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Pleomorphic xanthoastrocytoma (PXA) is a rare, low-grade glioma (World Health Organization Grade II) that most often presents in the first two decades of life. We summarize and present our institutional experience in the management of these tumors. All patients managed for PXA at the University of California San Francisco were retrospectively identified through chart review. Patient demographics, tumor characteristics, management, and follow-up were extracted using medical records. Primary endpoints were overall (OS) and progression-free survival (PFS). In total, nineteen patients were treated for PXA from 1993-2011. Clinical data were available for analysis in 18 patients. Median OS was 209.0 months after date of surgery, with both 5 year and 10 year survival rates of 94%. In this patient cohort, tumor grade (p = 0.07), age (p = 0.32), and extent of resection (p = 0.58) did not predict OS. The majority of tumors (78%) recurred. Median PFS was 21.7 months, with 5 year and 10 year recurrence-free rates of 28% and 22%. On univariate analysis, tumor grade (p = 0.01), but not age (p = 0.51), size (p = 0.30), or extent of resection (p = 0.21), was the only covariate predictive of PFS. In patients presenting with higher tumor grade, however, earlier recurrence was demonstrated. Furthermore, the majority of recurrences (36%) occurred within the first 6 months post-operatively, which indicates the need to closely follow patients for that time.

AB - Pleomorphic xanthoastrocytoma (PXA) is a rare, low-grade glioma (World Health Organization Grade II) that most often presents in the first two decades of life. We summarize and present our institutional experience in the management of these tumors. All patients managed for PXA at the University of California San Francisco were retrospectively identified through chart review. Patient demographics, tumor characteristics, management, and follow-up were extracted using medical records. Primary endpoints were overall (OS) and progression-free survival (PFS). In total, nineteen patients were treated for PXA from 1993-2011. Clinical data were available for analysis in 18 patients. Median OS was 209.0 months after date of surgery, with both 5 year and 10 year survival rates of 94%. In this patient cohort, tumor grade (p = 0.07), age (p = 0.32), and extent of resection (p = 0.58) did not predict OS. The majority of tumors (78%) recurred. Median PFS was 21.7 months, with 5 year and 10 year recurrence-free rates of 28% and 22%. On univariate analysis, tumor grade (p = 0.01), but not age (p = 0.51), size (p = 0.30), or extent of resection (p = 0.21), was the only covariate predictive of PFS. In patients presenting with higher tumor grade, however, earlier recurrence was demonstrated. Furthermore, the majority of recurrences (36%) occurred within the first 6 months post-operatively, which indicates the need to closely follow patients for that time.

KW - Cancer

KW - Glioma

KW - Management

KW - Pleomorphic xanthoastrocytoma

KW - Resection

KW - Treatment

KW - Tumor grade

UR - http://www.scopus.com/inward/record.url?scp=84908550418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908550418&partnerID=8YFLogxK

U2 - 10.1016/j.jocn.2014.04.002

DO - 10.1016/j.jocn.2014.04.002

M3 - Article

C2 - 24950906

AN - SCOPUS:84908550418

VL - 21

SP - 1767

EP - 1772

JO - Journal of Clinical Neuroscience

JF - Journal of Clinical Neuroscience

SN - 0967-5868

IS - 10

ER -